Finally, there is a pressing need to explore chemical inhibition of XPF–ERCC1 to sensitise cancer cells to platinum-based therapeutics and reduce drug resistance mediated by XPF-ERCC1. Equally, XPF-ERCC1 inhibitors could target cancer cell vulnerabilities including XPF-FANCM synthetic lethality relevant to FANCM-deficient tumours44 and potentially other platinum-sensitive contexts45. Here, FANCM is linked to cancer.